Publicacions (175) Publicacions de JOSÉ LUIS PABLOS ÁLVAREZ

2022

  1. Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

    International Journal of Infectious Diseases, Vol. 117, pp. 56-64

  2. Evidence of telomere attrition and a potential role for DNA damage in systemic sclerosis

    Immunity and Ageing, Vol. 19, Núm. 1

  3. Histological and structural effects of biodegradable polydioxanone stents in the rabbit trachea

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 62, Núm. 2

  4. Profibrotic Role of Inducible Heat Shock Protein 90α Isoform in Systemic Sclerosis

    Journal of immunology (Baltimore, Md. : 1950), Vol. 209, Núm. 1, pp. 38-48

  5. Proliferative synovitis, an ultrasound pattern associated with ACPA-positive patients and erosive disease in rheumatoid arthritis

    Clinical and experimental rheumatology, Vol. 40, Núm. 5, pp. 960-966

  6. Shorter telomere length is associated with COVID-19 hospitalization and with persistence of radiographic lung abnormalities

    Immunity and Ageing, Vol. 19, Núm. 1

  7. Tuberculosis

    Infectious Complications in Biologic and Targeted Therapies (Springer International Publishing), pp. 351-368

2021

  1. Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study

    Rheumatology (Oxford, England), Vol. 60, Núm. 2, pp. 667-674

  2. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study

    International Journal of Infectious Diseases, Vol. 105, pp. 487-494

  3. Controlled supply of tocilizumab during the COVID-19 pandemic and its influence on the treatment of rheumatological patients

    Revista Espanola de Salud Publica, Vol. 95

  4. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

    International Journal of Infectious Diseases, Vol. 105, pp. 319-325

  5. Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: An observational study

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 453-455

  6. Experimental observation of the geodesic acoustic frequency limit for the NBI-driven Alfvén eigenmodes in TJ-II

    Physics of Plasmas, Vol. 28, Núm. 7

  7. One-year, efficacy and safety open label study, with a single injection of a new hyaluronan for knee oa: The soya trial

    Journal of Pain Research, Vol. 14, pp. 2229-2237

  8. SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 6, pp. 1258-1262

  9. Synovial Immunohistological Biomarkers of the Classification of Undifferentiated Arthritis Evolving to Rheumatoid or Psoriatic Arthritis

    Frontiers in Medicine, Vol. 8